14 Heart Attack Clinical Trials in Chapel Hill, NC (2026)

Q: How do I join a clinical trial in Chapel Hill?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Chapel Hill research site will contact you.

Recruiting Heart Attack Studies in Chapel Hill

NCT06093672Recruiting

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients....

Chapel Hill, NCPHASE3220 participantsItalfarmaco

View Study Details

NCT05004051Recruiting

ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA

This is a Prospective Registry study to collect imaging and clinical data both on patients with aortic aneurysm disease undergoing serial monitoring and on patients pre and post-endovascular repair, u...

Chapel Hill, NC200 participantsViTAA Medical Solutions

View Study Details

NCT04588922Recruiting

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies

SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation grou...

Chapel Hill, NCPHASE1160 participantsSellas Life Sciences Group

View Study Details

NCT06934603Recruiting

Microplastic Exposure From Clear Aligner Wear (MPE)

An observational longitudinal study measuring microplastic exposure and physiologic uptake in orthodontic patients receiving clear aligner treatment....

Chapel Hill, NC150 participantsUniversity of North Carolina, Chapel Hill

View Study Details

NCT05401097Recruiting

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

This phase II study compares the order of treatment with ivosidenib or enasidenib and azacitidine plus venetoclax in treating older patients with acute myeloid leukemia with genetic changes in the IDH...

Chapel Hill, NCPHASE2125 participantsAlice Mims

View Study Details

NCT05756322Recruiting

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most ...

Chapel Hill, NCPHASE190 participantsLin BioScience, Inc

View Study Details

NCT06925542Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including ac...

Chapel Hill, NCPHASE180 participantsCRISPR Therapeutics

View Study Details

NCT04895436Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previousl...

Chapel Hill, NCPHASE275 participantsAbbVie

View Study Details

NCT06916806Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: • The study dur...

Chapel Hill, NCPHASE172 participantsAstraZeneca

View Study Details

NCT05442216Recruiting

Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

A treatment cycle is 28 days for Cycle 1 and Cycle 2. Tagraxofusp will be administered at 12 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 5 consecutive days (or 5 doses over a period not to...

Chapel Hill, NCPHASE253 participantsJoshua Zeidner

View Study Details

NCT07356154Recruiting

A Study of Revumenib and Mezigdomide in People With Leukemia

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias....

Chapel Hill, NCPHASE152 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07295847Recruiting

A Study of AZD0120 in Autoimmune Diseases

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with system...

Chapel Hill, NCPHASE127 participantsAstraZeneca

View Study Details

NCT07061951Recruiting

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

This phase II trial tests the effect of mirdametinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after a period of improvement (...

Chapel Hill, NCPHASE220 participantsNational Cancer Institute (NCI)

View Study Details

NCT06510491Recruiting

Epcoritamab in Previously Treated WM

This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study i...

Chapel Hill, NCPHASE220 participantsGottfried von Keudell, MD PhD

View Study Details

About Heart Attack Clinical Trials in Chapel Hill

A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.

There are currently 14 heart attack clinical trials recruiting participants in Chapel Hill, NC. These studies are seeking a combined 1,344 participants. Research is being sponsored by Italfarmaco, ViTAA Medical Solutions, Sellas Life Sciences Group and 10 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Heart Attack Clinical Trials in Chapel Hill — FAQ

Are there heart attack clinical trials in Chapel Hill?

Yes, there are 14 heart attack clinical trials currently recruiting in Chapel Hill, NC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chapel Hill?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chapel Hill research site will contact you about next steps.

Are clinical trials in Chapel Hill free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chapel Hill studies also compensate for your time and travel.

What heart attack treatments are being tested?

The 14 active trials in Chapel Hill are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.

Data updated July 17, 2026 from ClinicalTrials.gov